96-1323. New Animal Drugs For Use In Animal Feeds; Chlortetracycline, Sulfathiazole, Penicillin  

  • [Federal Register Volume 61, Number 18 (Friday, January 26, 1996)]
    [Rules and Regulations]
    [Pages 2414-2415]
    From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
    [FR Doc No: 96-1323]
    
    
    
    -----------------------------------------------------------------------
    
    
    DEPARTMENT OF HEALTH AND HUMAN SERVICES
    21 CFR Part 558
    
    
    New Animal Drugs For Use In Animal Feeds; Chlortetracycline, 
    Sulfathiazole, Penicillin
    
    AGENCY: Food and Drug Administration, HHS.
    
    ACTION: Final rule.
    
    -----------------------------------------------------------------------
    
    [[Page 2415]]
    
    
    SUMMARY: The Food and Drug Administration (FDA) is amending the animal 
    drug regulations to reflect approval of a supplemental new animal drug 
    application (NADA) filed by Fermenta Animal Health Co. The supplement 
    provides for use of fixed combination Type A medicated articles 
    containing chlortetracycline, sulfathiazole, and penicillin in making 
    Type B and C medicated swine feeds for swine from 10 pounds to 6 weeks 
    post-weaning.
    
    EFFECTIVE DATE: January 26, 1996.
    
    FOR FURTHER INFORMATION CONTACT: James F. McCormack, Center for 
    Veterinary Medicine (HFV-128), Food and Drug Administration, 7500 
    Standish Pl., Rockville, MD 20855, 301-594-1607.
    
    SUPPLEMENTARY INFORMATION: Fermenta Animal Health Co., 10150 North 
    Executive Hills Blvd., Kansas City, MO 64153, filed a supplement to 
    NADA 39-077 CSPTM 250 (20 grams (g) of chlortetracycline (as the 
    hydrochloride), 20 g of sulfathiazole, and 10 g of penicillin (as 
    penicillin procaine), per pound) and CSPTM 500 (40 g of 
    chlortetracycline (as the hydrochloride), 40 g of sulfathiazole, and 20 
    g of penicillin (as penicillin procaine), per pound). The NADA provides 
    for use of fixed combination Type A medicated articles to make Type B 
    and C medicated swine feeds for prestarter, starter, grower, and 
    finisher rations. The supplement provides for prestarter and starter 
    rations to be given to swine from 10 pounds of body weight to 6 weeks 
    postweaning for reduction of incidence of cervical abscesses, treatment 
    of bacterial enteritis (salmonellosis or necrotic enteritis caused by 
    Salmonella choleraesuis and vibrionic dysentery), maintenance of weight 
    gains in the presence of atropic rhinitis, increased rate of weight 
    gain and improved feed efficiency. The supplement is approved as of 
    January 26, 1996, and the regulations are amended in Sec. 558.155 (21 
    CFR 558.155) to reflect the approval. The basis of approval is 
    discussed in the freedom of information summary.
        In addition, the agency is revising the section heading for 
    Sec. 558.155 to reflect the active ingredients as on the label, i.e., 
    that the product is known as chlortetracycline with sulfathiazole and 
    penicillin, not as chlortetracycline hydrochloride with procaine 
    penicillin and sulfathiazole. The approvals paragraph does specify the 
    salts and esters approved for use.
        In Sec. 558.155(d) the feed consumption table is removed. The 
    performance or therapeutic claims of the product are based on ad 
    libitum consumption and not the minimum desired daily feed intake 
    consumption values reported in the table. This, together with changes 
    in weaning weights, renders the table obsolete. Also, the indications 
    for use are editorially revised to clarify the indications for each 
    feeding group.
        The product, chlortetracycline, sulfathiazole, and penicillin, in 
    combination in a Type A medicated article, is a new animal drug used to 
    make Type B and Type C medicated feeds. As provided in Sec. 558.4(b), 
    the combination drug product is a Category II drug because it requires 
    a withdrawal period at its lowest continuous use level. Therefore, it 
    requires an approved Form FDA 1900 for making Type B or Type C 
    medicated feeds as in approved NADA 39-077 and in Sec. 558.155.
        In accordance with the freedom of information provisions of part 20 
    (21 CFR part 20) and Sec. 514.11(e)(2)(ii) (21 CFR 514.11(e)(2)(ii)), a 
    summary of safety and effectiveness data and information submitted to 
    support approval of this application may be seen in the Dockets 
    Management Branch (HFA-305), Food and Drug Administration, rm. 1-23, 
    12420 Parklawn Dr., Rockville, MD 20857, between 9 a.m. and 4 p.m., 
    Monday through Friday.
        Under section 512(c)(2)(F)(iii) of the Federal Food, Drug, and 
    Cosmetic Act (21 U.S.C. 360b(c)(2)(F)(iii)), this supplemental approval 
    does not qualify for marketing exclusivity because the supplement does 
    not contain reports of new clinical or field investigations (other than 
    bioequivalence or residue studies) or human food safety studies (other 
    than bioequivalence or residue studies) essential to the approval and 
    conducted or sponsored by the applicant.
        The agency has determined under 21 CFR 25.24(d)(1)(i) that this 
    action is of a type that does not individually or cumulatively have a 
    significant effect on the human environment. Therefore, neither an 
    environmental assessment nor an environmental impact statement is 
    required.
    
    List of Subjects in 21 CFR Part 558
    
        Animal drugs, Animal feeds.
        Therefore, under the Federal Food, Drug, and Cosmetic Act and under 
    authority delegated to the Commissioner of Food and Drugs and 
    redelegated to the Center for Veterinary Medicine, 21 CFR part 558 is 
    amended as follows:
    
    PART 558--NEW ANIMAL DRUGS FOR USE IN ANIMAL FEEDS
    
        1. The authority citation for 21 CFR part 558 continues to read as 
    follows:
    
        Authority: Sec. 512, 701 of the Federal Food, Drug, and Cosmetic 
    Act (21 U.S.C. 360b, 371).
    
        2. Section 558.155 is amended by revising the section heading and 
    paragraphs (d)(2) and (d)(3) to read as follows:
    
    
    Sec. 558.155  Chlortetracycline, sulfathiazole, penicillin.
    
    -* * * * *
        (d) *  *  *
        (2) Indications for use. For reduction of incidence of cervical 
    abscesses. Treatment of bacterial enteritis (salmonellosis or necrotic 
    enteritis caused by Salmonella choleraesuis and vibrionic dysentery). 
    Maintenance of weight gains in the presence of atrophic rhinitis. Swine 
    10 pounds of body weight to 6 weeks post-weaning: Increased rate of 
    weight gain and improved feed efficiency. Swine 6 to 16 weeks post-
    weaning: Increased rate of weight gain.
        (3) Limitations. For swine raised in confinement (dry-lot) or on 
    limited pasture. Feed as sole ration. Withdraw 7 days prior to 
    slaughter.
    
        Dated: January 3, 1996.
    Robert C. Livingston,
    Director, Office of New Animal Drug Evaluation, Center for Veterinary 
    Medicine.
    [FR Doc. 96-1323 Filed 1-25-96; 8:45 am]
    BILLING CODE 4160-01-F
    
    

Document Information

Effective Date:
1/26/1996
Published:
01/26/1996
Department:
Health and Human Services Department
Entry Type:
Rule
Action:
Final rule.
Document Number:
96-1323
Dates:
January 26, 1996.
Pages:
2414-2415 (2 pages)
PDF File:
96-1323.pdf
CFR: (1)
21 CFR 558.155